Company history

In October 2005 Mitsubishi Chemical and Mitsubishi Pharma executed a joint share transfer to create Mitsubishi Chemical Holdings, listed in Tokyo and Osaka with combined revenue of ¥2,189.4bn. Putting commodity chemicals and pharmaceuticals under one parent was an unusual choice for a Japanese integrated chemical maker, and the reasoning was arithmetic rather than sentiment: in FY2005 petrochemicals supplied roughly 45% of consolidated revenue but only about 25% of operating profit, while pharmaceuticals produced about 27% of it — and across the ten years to FY2005, the two segments' profits had moved in opposite directions in seven. One cyclical business, one research-driven business, hedging each other under a single capital structure.

The design deliberately stopped there. The operating companies stayed separate and self-governing; only strategy was centralised. That was the point of a holding company — and it was also why the group's actual degree of integration would stay low for more than a decade. The succession made the intent explicit: president Tomizawa Ryuichi, saying he was good at building an earnings base but not at drawing a growth strategy, named Kobayashi Yoshimitsu — the engineer who had taken the group's DVD-media subsidiary to world number one — as his successor. Kobayashi took over in April 2007 with a slogan, KAITEKI management, and a mandate to expand.

He bought roughly one company every four years. Mitsubishi Plastics was taken private by share exchange in October 2007, the same month Mitsubishi Pharma merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma; Mitsubishi Rayon was acquired by tender offer in March 2010, weeks after the group had posted a ¥67.2bn net loss, bringing in carbon fibre, acrylics and a world-leading MMA position; and in November 2014 the tender offer for Taiyo Nippon Sanso added Japan's largest industrial-gas business as a third pillar. Revenue passed ¥3tn. Every one of these purchases was slotted under the holding company as another box on the chart, and each time the merging of the underlying operations was deferred to the next mid-term plan.

Ochi Hitoshi became president in June 2015 and set about connecting what had been bought. His mid-term plan APTSIS20 established four regional headquarters meant to run their territories autonomously, and he spoke of pushing a fifth of R&D spending into cross-industry joint research. The structure appeared; the authority did not. As the group later conceded, the regional headquarters never moved beyond coordination into actually running businesses, and decision-making stayed head-office-centred and product-push rather than market-led.

The centrepiece came in April 2017, when Mitsubishi Chemical, Mitsubishi Plastics and Mitsubishi Rayon merged into a single operating company, Mitsubishi Chemical Corporation — twelve years after the holding company that was supposed to unify them. It was Japan's largest chemical maker as a single entity, with revenue near ¥3tn; 56 business units across the three companies were consolidated into 26 and reorganised into ten divisions, and Ochi, holding both presidencies, targeted ¥50bn of synergies over four years. Legally it was one company. Operationally it was three islands: each of the merged firms was itself an accumulation of earlier acquisitions, more than ten ERP systems ran side by side, and years later it was still impossible to order a Japanese-made product from the United States. The financial statements consolidated; the business did not.

In March 2020 the group took Mitsubishi Tanabe Pharma fully private by tender offer and squeeze-out, ending the parent–subsidiary listing and completing the pharmaceutical pillar. Within the same month COVID-19 and a collapse in petrochemical margins hit, and FY2020 closed with a net loss of ¥7.6bn — the first since the financial crisis, and proof that owning a differently-shaped business had not absorbed the cycle after all. That October Taiyo Nippon Sanso converted to a holding company as Nippon Sanso Holdings, staying listed and gaining autonomy. Ochi's term ended in March 2021 with the portfolio question wide open, and the board answered it by hiring from outside Japan.

In April 2021 Jean-Marc Gilson, formerly of Dow Corning, became president — the first foreign chief executive of a major Japanese integrated chemical company. His December 2021 plan, Forging the Future, rested on five pillars: a simpler organisation, cost restructuring, the carve-out of petrochemicals, a shift to specialities, and a single ERP. His diagnosis was blunt — the company had succeeded by being Japan-centred while growth was happening abroad, and it was organised to push products rather than serve markets; it had a battery sales team in the United States but no team covering automotive as a whole. The petrochemical carve-out in particular raised expectations of an industry-wide restructuring. In July 2022 the parent renamed itself Mitsubishi Chemical Group, dropping "Holdings" to signal one-company operation, and set semiconductors, OLED, MLCC and GaN substrates as growth fields.

The separation never happened. Chinese capacity additions drove Asian MMA prices from about $2,100 a tonne in July 2022 to $1,600 by September; the Cassel plant in the UK was not restarted and a new US alpha-process line was deferred. The market that was supposed to buy the petrochemical business shrank precisely while it was being prepared for sale, and the carve-out stalled at the planning stage. Inside the company, Gilson's pace produced heavy attrition and a visible gap between management and staff.

In June 2023 Chikumoto Manabu, a career insider, took over and distanced himself from that line, arguing that Mitsubishi Chemical could not lead an industry restructuring before fixing its own earning power. At a November 2024 briefing he delivered an unusually direct self-assessment — that selection and concentration had not been carried through, and that the turmoil had separated management from employees — alongside a new vision, KAITEKI Vision 35. Its keyword was "connect": making money by finally joining up the technology, people and knowledge that two decades of acquisition had left scattered. Then in February 2025 the group agreed to sell Mitsubishi Tanabe Pharma to Bain Capital for about ¥510bn — the same asset it had bought out for roughly ¥500bn five years earlier, and the first time it had removed an entire pillar of the structure it spent twenty years assembling. The proceeds went not to the next acquisition but to a ¥50bn buyback and a 35% payout ratio.